Global /United States /Healthcare /Drug Manufacturers - General /XBIO

Xenetic Biosciences, Inc.

XBIO

• NASDAQ: XBIO • Delayed

3.00USD -4.2%

As of 13 June 2026, Xenetic Biosciences, Inc. has a market cap of $6.87M USD, ranking #43142 globally and #5523 in the United States. It ranks #3815 in the Healthcare sector, and #1232 in the Drug Manufacturers - General industry.

Global Rank

43142

Country Rank

5523

Sector Rank

3815

Industry Rank

1232

Key Stats

Market Cap

$6.87MUSD

Enterprise Value

-$705.97KUSD

Revenue (TTM)

$2.98MUSD

Net Income (TTM)

-$2.68MUSD

Profit Margin

-90%

PS Ratio

2.4

PB Ratio

1.0

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

James Parslow open_in_new

Employees

Website

xeneticbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-4.2%	-5.4%	8.8%	19%	-17%	36%	5.7%	-30%	-86%

News

XBIO Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	XBIO Xenetic Biosciences Inc ISIN: US9840156023 Shares Out.: Shares Outstanding: 2.291M¹ Shares Float: 1.83M² TV: TradingView: NASDAQ: XBIO SA: Stock Analysis: NASDAQ: XBIO YF: Yahoo Finance: XBIO GF: Google Finance: NASDAQ: XBIO NQ: NASDAQ: XBIO BA: Barron's: XBIO MS: Morningstar: XNAS: XBIO	3.00 USD	TV: TradingView: NASDAQ: XBIO SA: Stock Analysis: NASDAQ: XBIO YF: Yahoo Finance: XBIO GF: Google Finance: NASDAQ: XBIO NQ: NASDAQ: XBIO BA: Barron's: XBIO MS: Morningstar: XNAS: XBIO

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company’s product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 11M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 8M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 5M%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 4M%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 2M%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 2M%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 5M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 4M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 4M%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 3M%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 2M%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 2M%	14.6	United Kingdom

chevron_leftBack